Who are PEGylated Recombinant Factor VIII's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xyntha, Kogenate (BAY 14-2222), von Willebrand factor, Alphanate SD/HT, OBIZUR, Coagulation Factor VIII.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegylated-recombinant-factor-viii.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

PEGylated Recombinant Factor VIII — Competitive Intelligence Brief

PEGylated Recombinant Factor VIII (PEGylated Recombinant Factor VIII) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Factor VIII replacement therapy. Area: Hemophilia A.

phase 3 Factor VIII replacement therapy Factor VIII Hemophilia A Biologic Live · refreshed every 30 min

Target snapshot

PEGylated Recombinant Factor VIII (PEGylated Recombinant Factor VIII) — Baxalta now part of Shire. PEGylated Recombinant Factor VIII is a recombinant form of human factor VIII that is modified with polyethylene glycol (PEG) to prolong its half-life.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PEGylated Recombinant Factor VIII TARGET	PEGylated Recombinant Factor VIII	Baxalta now part of Shire	phase 3	Factor VIII replacement therapy	Factor VIII
Xyntha	xyntha	Pfizer	marketed	Recombinant protein therapy	Coagulation factor VIII
Kogenate (BAY 14-2222)	Kogenate (BAY 14-2222)	Bayer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
von Willebrand factor	von Willebrand factor	National Center for Research Resources (NCRR)	marketed	Coagulation factor replacement	Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site
Alphanate SD/HT	Alphanate SD/HT	Grifols Biologicals, LLC	marketed	Clotting factor concentrate; Factor VIII replacement therapy	Factor VIII (antihemophilic factor)
OBIZUR	OBIZUR	Baxalta now part of Shire	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Coagulation Factor VIII	Coagulation Factor VIII	Beijing Children's Hospital	marketed	Coagulation factor replacement	Coagulation Factor VIII (antihemophilic factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Factor VIII replacement therapy class)

Baxalta now part of Shire · 2 drugs in this class
Bayer · 1 drug in this class
CSL Behring · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PEGylated Recombinant Factor VIII — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-recombinant-factor-viii. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab